All sponsors

Axsome Therapeutics, Inc. $AXSM

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-310
RECRUITING7
READOUTS ≤12 MONTHS2
Open Axsome Therapeutics, Inc. on the live radar map → 📅 $AXSM readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
ENGAGE
NCT06413433
P3RecruitingBinge-Eating Disorder4502026-12 (+12 mo)
Solriamfetol 150 mg
NCT06568367
P3RecruitingExcessive Sleepiness; Shift-work Disorder5202026-12
Solriamfetol
NCT06878976
P3Enrolling by invitationBinge-Eating Disorder2362027-12 (+12 mo)
SUMMIT
NCT07766655
P3RecruitingSmoking Cessation7052027-12
Solriamfetol
NCT07773883
P3Enrolling by invitationADHD3002027-12
FORWARD
NCT07398417
P3RecruitingFibromyalgia6202028-03
AXS-14 (esreboxetine)
NCT07637162
P3Enrolling by invitationFibromyalgia3002028-05
Solriamfetol Dose A
NCT07717879
P3RecruitingADHD4682028-06-30
Solriamfetol Dose A
NCT07717892
P3RecruitingADHD4682028-06-30
CLARITY
NCT07484217
P3RecruitingMajor Depressive Disorder With Excessive Daytime Sleepiness Symptoms5082028-12